Catalent, Inc. (NYSE:CTLT) fell 8.8% on Tuesday . The stock traded as low as $101.86 and last traded at $101.94. 54,452 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 1,026,055 shares. The stock had previously closed at $111.78.
A number of brokerages have issued reports on CTLT. UBS Group raised their price objective on shares of Catalent from $115.00 to $135.00 and gave the company a “buy” rating in a research note on Wednesday, February 3rd. Argus increased their target price on Catalent from $130.00 to $140.00 and gave the company a “buy” rating in a research note on Tuesday, March 2nd. They noted that the move was a valuation call. JPMorgan Chase & Co. boosted their price objective on shares of Catalent from $110.00 to $130.00 and gave the company an “overweight” rating in a report on Friday, January 8th. Zacks Investment Research cut Catalent from a “buy” rating to a “hold” rating in a report on Monday. Finally, Morgan Stanley lifted their target price on Catalent from $115.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, February 3rd. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Catalent currently has a consensus rating of “Buy” and an average target price of $125.67.
The company has a market cap of $17.65 billion, a P/E ratio of 65.68, a price-to-earnings-growth ratio of 2.68 and a beta of 1.50. The stock has a 50 day moving average price of $108.38 and a two-hundred day moving average price of $106.35. The company has a quick ratio of 2.14, a current ratio of 2.56 and a debt-to-equity ratio of 0.97.
Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, May 4th. The company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.09. The firm had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $994.28 million. Catalent had a return on equity of 14.20% and a net margin of 9.25%. The company’s quarterly revenue was up 38.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.50 EPS. Equities analysts anticipate that Catalent, Inc. will post 2.35 EPS for the current year.
In other Catalent news, SVP Kay A. Schmidt sold 1,400 shares of the firm’s stock in a transaction on Monday, March 22nd. The stock was sold at an average price of $105.77, for a total transaction of $148,078.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO John R. Chiminski sold 42,220 shares of Catalent stock in a transaction on Thursday, March 18th. The shares were sold at an average price of $105.16, for a total value of $4,439,855.20. The disclosure for this sale can be found here. Insiders sold a total of 74,871 shares of company stock valued at $7,997,007 in the last quarter. Corporate insiders own 1.00% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of CTLT. BlackRock Inc. grew its stake in Catalent by 0.5% during the fourth quarter. BlackRock Inc. now owns 13,286,853 shares of the company’s stock worth $1,382,764,000 after buying an additional 68,225 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Catalent by 0.6% in the 4th quarter. JPMorgan Chase & Co. now owns 5,332,447 shares of the company’s stock valued at $554,950,000 after buying an additional 31,411 shares in the last quarter. Nuveen Asset Management LLC lifted its holdings in shares of Catalent by 0.8% during the 4th quarter. Nuveen Asset Management LLC now owns 1,485,969 shares of the company’s stock worth $154,645,000 after acquiring an additional 12,130 shares during the period. Norges Bank acquired a new stake in shares of Catalent during the 4th quarter worth approximately $149,074,000. Finally, Bank of New York Mellon Corp increased its stake in Catalent by 5.0% in the fourth quarter. Bank of New York Mellon Corp now owns 1,362,467 shares of the company’s stock valued at $141,793,000 after acquiring an additional 64,787 shares during the last quarter. 97.84% of the stock is owned by institutional investors and hedge funds.
Catalent Company Profile (NYSE:CTLT)
Catalent, Inc, together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.
See Also: Dividend Achievers